Belantamab Mafodotin or Lenalidomide Maintenance
Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 94 patients (estimated)
- Sponsors
- MD Anderson Cancer Center
- Tags
- Antibody Drug Conjugate (ADC), Immunomodulatory Drug (IMiD), B-Cell Maturation Antigen (BCMA), Maintenance, Randomization
- Trial Type
- Treatment
- Last Update
- 3 months ago
- SparkCures ID
- 1900
- NCT Identifier
- NCT05091372
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.